Clinical trial
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287
Study timeline
Study start (actual)2005-07-28Date precision: day
Registry last updated2025-01-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Breast Cancerunresolved
Interventions
Sponsors & collaborators
Mapped research locations
DallasTexas, United States4HoustonTexas, United States1ChicagoIllinois, United States1St LouisMissouri, United States1SeattleWashington, United States1BirminghamAlabama, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1MinneapolisMinnesota, United States1DenverColorado, United States1AustinTexas, United States1RochesterNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00248287 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.